Biogen (BIIB) Intangibles (2009 - 2026)
Biogen (BIIB) posted quarterly Intangibles of $9.1 billion for Q1 2026, down 5.54% year-over-year from $9.6 billion in Q1 2025, and down 1.36% on a QoQ basis from $9.2 billion in Q4 2025.
Biogen (BIIB) Intangibles (2009 - 2026) Analysis & Trends
Biogen (BIIB) has reported Intangibles for 18 consecutive years, with $9.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 5.54% year-over-year to $9.1 billion; the TTM figure through Mar 2026 stood at $9.1 billion (down 5.54% YoY), while the FY2025 annual figure was $9.2 billion, down 5.29% from the prior year.
- Intangibles came in at $9.1 billion for Q1 2026 at Biogen, down from $9.2 billion in the prior quarter.
- The five-year high for Intangibles was $9.8 billion in Q3 2024, with the low at $100.0 million in Q3 2023.
- Average Intangibles over 5 years is $6.0 billion, with a median of $8.3 billion recorded in 2024.
- Across the five-year window, Intangibles plunged 95.02% in 2023 and surged 9705.5% in 2024, its largest moves.
- Year by year, Intangibles stood at $1.9 billion in 2022, then surged by 352.03% to $8.4 billion in 2023, then climbed by 15.88% to $9.7 billion in 2024, then slipped by 5.29% to $9.2 billion in 2025, then fell by 1.36% to $9.1 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $9.1 billion, $9.2 billion, and $9.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 9.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.05 Bn |
| Dec 31, 2025 | 9.18 Bn |
| Sep 30, 2025 | 9.33 Bn |
| Jun 30, 2025 | 9.47 Bn |
| Mar 31, 2025 | 9.58 Bn |
| Dec 31, 2024 | 9.69 Bn |
| Sep 30, 2024 | 9.81 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Mar 31, 2024 | 8.28 Bn |
| Dec 31, 2023 | 8.36 Bn |
| Sep 30, 2023 | 100.00 Mn |
| Jun 30, 2023 | 1.78 Bn |
| Mar 31, 2023 | 1.81 Bn |
| Dec 31, 2022 | 1.85 Bn |
| Sep 30, 2022 | 2.01 Bn |
| Jun 30, 2022 | 2.08 Bn |
| Mar 31, 2022 | 2.15 Bn |
| Dec 31, 2021 | 2.22 Bn |
| Sep 30, 2021 | 2.29 Bn |
| Jun 30, 2021 | 2.39 Bn |